The addition of a covalent warhead permitted this to act at G12C, eliciting anti-proliferative effects in the NCI-H358 KRAS G12C mutant lung cancer cell line that were comparable to that of sotorasib (26 nM potency) (Bröker et al., 2022). The gene discussed is KRAS; the disease is lung carcinoma.